On November 18, local time, Pfizer announced that it had reached an exclusive licensing agreement with Starry Pharmaceuticals. Under the agreement, Pfizer obtained exclusive development, production and commercialization rights for three vivo chimeric antigen receptor T cell projects aimed at treating autoimmune diseases, which are in the pre-IND filing stage, in regions outside of Greater China. In addition, Pfizer has obtained the right to use Starrui Pharmaceuticals' proprietary in-vivo CAR-T technology in the field of inflammatory and immune diseases and oncology, has the right to choose to obtain exclusive licenses for candidate compounds developed in other cooperative studies, and can choose to expand the geographical scope of various authorizations to the Greater China region.

Zhitongcaijing · 2d ago
On November 18, local time, Pfizer announced that it had reached an exclusive licensing agreement with Starry Pharmaceuticals. Under the agreement, Pfizer obtained exclusive development, production and commercialization rights for three vivo chimeric antigen receptor T cell projects aimed at treating autoimmune diseases, which are in the pre-IND filing stage, in regions outside of Greater China. In addition, Pfizer has obtained the right to use Starrui Pharmaceuticals' proprietary in-vivo CAR-T technology in the field of inflammatory and immune diseases and oncology, has the right to choose to obtain exclusive licenses for candidate compounds developed in other cooperative studies, and can choose to expand the geographical scope of various authorizations to the Greater China region.